Combined measurement of plasma cystatin C and low-density lipoprotein cholesterol: A valuable tool for evaluating progressive supranuclear palsy. (July 2018)

• Record Type: Journal Article
• Authors: Weng, Ruihui; Wei, Xiaobo; Yu, Bin; Zhu, Shuzhen; Yang, Xiaohua; Xie, Fen; Zhang, Mahui; Jiang, Ying; Feng, Zhong-Ping; Sun, Hong-Shuo; Xia, Ying; Jin, Kunlin; Chan, Piu; Wang, Qing; Gao, Xiaoya
• Is Part Of: Parkinsonism & related disorders. Volume 52(2018)
• Page Start: 37
• Page End: 42
• Publication Date: 2018-07
• Subjects: Progressive supranuclear palsy -- Cystatin C -- Low-density lipoprotein cholesterol -- Neurocognitive disorder; AD Alzheimer disease -- ALS Amyotrophic Lateral Sclerosis -- Apo B apolipoprotein B -- AUC area under the curve -- Cys C Cystatin C -- GDS Geriatric Depression Scale -- HDL-C High-density lipoprotein cholesterol -- LDL low-density lipoprotein -- LDL-C low-density cholesterol lipoprotein -- MMSE Mini-Mental State Examination -- NINDS the National Institute of Neurological Disorders and Stroke and Society -- NMSS the Non-Motor Symptoms Scale -- PSP Progressive supranuclear palsy -- PSP-RS Progressive Supranuclear Palsy-Richardson's syndrome -- PSPRS Progressive Supranuclear Palsy-Rating Scale -- ROC Receivers operating characteristic curves -- S&E-ADL the Schwab & England activities of daily living scale -- TC total cholesterol -- UPDRS unified PD rating scale; Parkinson's disease -- Periodicals; Movement disorders -- Periodicals; Movement Disorders -- Periodicals; Nerve Degeneration -- Periodicals; Nervous System Diseases -- Periodicals; Parkinson Disease -- Periodicals; Tremor -- Periodicals; Parkinson, Maladie de -- Périodiques; Parkinson's disease; 616.833
• DOI: 10.1016/j.parkreldis.2018.03.014
• Languages: English
• ISSNs: 1353-8020

Abstract

Abstract: Introduction: Progressive supranuclear palsy (PSP) was previously thought as a cause of atypical Parkinsonism. Although Cystatin C (Cys C) and low-density cholesterol lipoprotein-C (LDL-C) are known to play critical roles in Parkinsonism, it is unknown whether they can be used as markers to distinguish PSP patients from healthy subjects and to determine disease severity. Methods: We conducted a cross-sectional study to determine plasma Cys C/HDL/LDL-C levels of 40 patients with PSP and 40 healthy age-matched controls. An extended battery of motor and neuropsychological tests, including the PSP-Rating Scale (PSPRS), the Non-Motor Symptoms Scale (NMSS), Geriatric Depression Scale (GDS) and Mini-Mental State Examination (MMSE), was used to evaluate the disease severity. Receiver operating characteristic (ROC) curves were adopted to assess the prognostic accuracy of Cys C/LDL-C levels in distinguishing PSP from healthy subjects. Results: Patients with PSP exhibited significantly higher plasma levels of Cys C and lower LDL-C. The levels of plasma Cys C were positively and inversely correlated with the PSPRS/NMSS and MMSE scores, respectively. The LDL-C/HDL-C ratio was positively associated with PSPRS/NMSS and GDS scores. The ROC curve for the combination of Cys C and LDL-C yielded a better accuracy for distinguishing PSP from healthy subjects than the separate curves for each parameter. Conclusions: Plasma Cys C and LDL-C may be valuable screening tools for differentiating PSP from healthy subjects; while they could be useful for the PSP intensifies and severity evaluation. A better understanding of Cys C and LDL-C may yield insights into the pathogenesis of PSP. Highlights: Higher plasma Cys C levels in patients with PSP than in healthy controls. Lower plasma LDL-C levels in patients with PSP than in healthy controls. Significantly positive correlation of Cys C/LDL-C/HDL-C ratio in PSP patients. Better discrimination between PSP patients and healthy subjects by the ROC curve of combined measurement of Cys C and LDL-C.